Bullboard - Stock Discussion Forum VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in... see more

Add To Watchlist

TSXV:VPT - Post Discussion

VentriPoint Diagnostics Ltd > VMS+ V3.2 and submitted V4.0 to FDA for 510(k) clearance.

View:

Post by jopatclo on Jun 17, 2024 6:11am

VMS+ V3.2 and submitted V4.0 to FDA for 510(k) clearance.

During the past several months Ventripoint has released VMS+ V3.2 and submitted V4.0 to FDA for 510(k) clearance. We are now preparing for product launch and market entry for what we believe is a product that promises true benefits for patients, clinicians and healthcare providers.

Developing great products is no longer enough to succeed. The “build it, and they will come” mindset will no longer lead to success in an increasingly competitive and “noisy” environment. As medical products become more sophisticated and customers are facing more demands on their time, focus and budgets, the path to market awareness and adoption has become much more complicated.

To better position Ventripoint to navigate this new reality we are evolving the company towards a market-driven culture in which the product management discipline will function to align our development team and products with customer need. We are building the insights and capability to better articulate the benefits and value of VMS+ to key segments and indications, and will focus future development activities on strengthening the user experience.

This takes a multi-disciplinary approach that combines deep technical, clinical and market knowledge. We believe this higher level of expertise will drive our commercial success and become a source of competitive advantage. We are continuing to recruit team members with the experience and unique skills to create impact, and look forward to sharing our successes as VMS+ is integrated into clinical practice.